| 摘要 |
<p>The present invention relates to the use of GATA2, PAK4, RASA1 and/or a modulator, in particular an inhibitor of miR-24 for the manufacture of a medicament for the treatment and/or prevention of ischemia and for the induction of angiogenesis. The present invention also relates to an in vitro method for diagnosing ischemia or prevalence for ischemia, to a method for identifying a modulator of miR-24, GATA2, PAK4 and/or RASA1. In addition the present invention relates to a kit comprising an antagomir and/or an antisense oligonucleotide essentially complementary to SEQ ID NO: 1, to endothelial cells devoid of expressing functional miR-24, and to a non-human, transgenic animal comprising these endothelial cells.</p> |
